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It is not knownwhether the low infectivity and low virion-associ-
ated polymerase activity of humanT-cell lymphotropic virus type-1
(HTLV-1) are due to the quantity or quality of the reverse tran-
scriptase (RT), because the protein has not yet been fully character-
ized. We have developed anti-RT antibodies and constructed
HTLV-1 expression plasmids that express truncated or hemagglu-
tinin-tagged Pol polyproteins to examine the maturation and compo-
sition of HTLV-1 RT. We detected virion-associated proteins corre-
sponding to RT-integrase (IN) (pr98) and RT (p62) as well as smaller
proteins containing the polymerase (p49) or RNase H domains. We
have identified the amino acid sequences in the Pol polyprotein that
are cleavedbyHTLV-1protease toyieldRTand IN.Wehavealso iden-
tified the cleavage sites within RT that give rise to the p49 polymerase
fragment. Immunoprecipitation of an epitope-tagged p62 subunit
coprecipitated p49, indicating that the HTLV-1 RT complex can exist
as a p62/p49 heterodimer analogous to the RT of HIV-1 (p66/p51).
Human T-cell lymphotropic virus type-1 (HTLV-1)2 is an oncogenic
retrovirus belonging to the deltaretrovirus genus, which includes
HTLV-2, -3, and -4, simian T-cell lymphotropic viruses, and bovine
leukemia virus. As with many other retroviruses, HTLV-1 uses riboso-
mal frameshifting to regulate the relative expression ofGag proteins and
the viral replication enzymes. In many retroviruses, including human
immunodeficiency virus (HIV) and Rous sarcoma virus (RSV), protein
synthesis that initiates from the gag start codon gives rise to both Gag
and Gag-Pol polyprotein precursors. A ribosomal frameshift site
encoded either at the 5-end of pol (HIV) or at the 3-end of gag (RSV)
allows the synthesis of the Gag-Pol polyprotein (1, 2). In contrast, the
pro gene of some retroviruses, such as HTLV, mouse mammary tumor
virus, and Mason-Pfizer monkey virus, is in a separate reading frame
from both gag and pol. Thus, the expression of Gag-Pol polyprotein in
these retroviruses involves two ribosomal frameshifts: one where gag
and pro overlap and the second within the pro/pol overlap (3–11). In
these viruses, three polyprotein precursors are synthesized. In HTLV-1,
they areGag (Pr53), Gag-Pro (Pr76), andGag-Pro-Pol (Pr180). Based on
in vitro translation of viral RNA, the molar ratio of the Gag, Gag-Pro,
and Gag-Pro-Pol polyproteins was estimated to be about 100:10:1 (12).
This means that the relative amounts of Pol to Gag produced by
HTLV-1 would be 5–10-fold less than the amount present in single-
frameshift retroviruses, such as HIV and RSV (1, 2) and 3–4-fold less
than the amount found in the other two-frameshift retroviruses: mouse
mammary tumor virus and Mason-Pfizer monkey virus (13–15).
Retroviral pol genes encode RT and integrase (IN), which are
required for the replication and integration of the viral genome. The Pol
precursor is enzymatically cleaved by the viral protease to yield the
subunits of the RT complex. The reverse transcriptases of HIV-1, RSV,
and murine leukemia virus are the prototypes of three distinct forms of
RT (16). The heterodimeric RSVRT consists of an RT-IN subunit and
the RT  subunit (17). HIV-1 RT is a smaller heterodimer, where the
larger subunit (p66) contains both polymerase and RNase H domains,
and the smaller subunit (p51) corresponds closely, but not exactly, to
the polymerase domain (18–22). In contrast to the RTs ofHIV andRSV,
the RT of murine leukemia virus is a monomer in solution, although it
may dimerize when it binds nucleic acid (23, 24).
Shortly after the virus was identified in 1980, some basic properties of
the virion-associated HTLV-1 RT were defined. The virion-associated
enzyme hadDNApolymerase and RNaseH activity andwas reported to
have a molecular mass of about 95 kDa (25). However, neither the Pol
cleavage products present inHTLV-1 virions nor their quaternary orga-
nization in the RT complex are known. Sequence alignments of diverse
retroviral pol genes have been used to try to predict theHTLV-1 polym-
erase, ribonuclease H, and integrase functional domains (26–28), and
based on these predictions, attemptsweremade to express recombinant
HTLV-1 RT (28, 29). However, these sequence alignments did not cor-
rectly predict the N terminus of HTLV-1 RT. We recently demon-
strated that the N-terminal residue of RT is not encoded immediately
adjacent to the C terminus of protease (PR), as it is in other retroviruses
(28, 30, 31). Instead, there is an 8-amino acid peptide, p1, that separates
PR and RT. Removal of p1 from the C terminus of PR is not required for
proteolytic activity, but removal of p1 from the N terminus of RT is
essential for virion-associated RT activity and infectivity (30).
In order to define HTLV-1 Pol processing and to characterize the
mature RT, we constructed virus expression plasmids that generate
VLPs containing 10-fold higher levels of Pol than wild-type virions.
Immunoblotting of VLPs from transfected cells revealed Pol cleavage
products corresponding to RT-IN, RT (p62), polymerase (p49), and
RNase H (p15). Pol maturation was analyzed by immunoblotting pro-
teins fromwild type andmutantVLPs. Protease cleavage siteswithin Pol
were then mapped by mutagenesis or by in vitro PR cleavage reactions.
Immunoprecipitation of an epitope-tagged version of p62 RT from
HTLV-1 VLPs co-precipitated the untagged p49 polymerase subunit,
suggesting that the virion-associatedHTLV-1 RT can exist as a p62/p49
heterodimer, analogous to the HIV-1 p66/p51 RT complex.
MATERIALS ANDMETHODS
Plasmids—pCMVHT-1env is an HTLV-1 expression plasmid that
produces virus-like particles (VLPs) that lack the Env glycoproteinwhen
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the plasmid is transfected into cultured cells (32). pCMVHT-1env-
polfs was constructed from pCMVHT-1env by inserting a deoxycyti-
dine residue into the pro/pol ribosomal frameshift site using site-di-
rected mutagenesis. This mutant plasmid expresses the HTLV-1 Gag-
Pro-Pol polyprotein precursor via a single frameshifting event. The level
of Gag-Pro-Pol expression is about 10-fold higher than from the parent
HTLV-1 plasmid. Unless otherwise indicated, the following Pol muta-
tions were constructed in the pCMVHT-1env-polfs backbone. Pol is
880 amino acids long, and our numbering of the 880-amino acid Pol is
based on the N terminus of RT having the sequence GLEHLP (30). The
IN mutation creates a stop codon at amino acid 718; the RH muta-
tion creates a stop codon at amino acid 514; and the RT mutation
creates a premature stop codon at amino acid 311. The F442am muta-
tion creates a stop codon at amino acid residue 442 of Pol. An 11-amino
acid hemagglutinin (HA) epitope tag followed by a stop codon was
inserted after amino acid 581 to construct the RH-HA vector; the HA
tag is inserted immediately upstream of the predicted RT/IN cleavage
site. An HA tag was also inserted after amino acid residue 738, in the
integrase domain, to make IN-HA. To construct the IN-HA-psite plas-
mid, the amino acids at the predicted RT/IN cleavage site (residues
582–585 of Pol) were changed from VLQL to GAQA.
Cell Lines, Transfections, and Preparation of Virus-like Particles—
The human kidney line 293T was maintained in Dulbecco’s modified
Eagle’s medium, supplemented with 10% fetal bovine serum, L-gluta-
mine, and antibiotics. Virus stocks were generated by transfection of
293T cells with expression plasmids by calcium phosphate co-precipi-
tation. The culture medium was replaced 16 h after transfection with
Advanced Dulbecco’s modified Eagle’s medium, supplemented with 2%
ultralow IgG fetal bovine serum, GlutaMAX-1, and antibiotics. Virus-
containing supernatants were collected 24 h later. Transfected cell
supernatants were cleared by low speed centrifugation and filtered
through 0.45-mpore size low protein-binding filters (Millipore). VLPs
were concentrated by ultracentrifugation through a 20% glycerol cush-
ion in a Ti70 rotor at 30,000 rpm for 90 min at 4 °C.
The HTLV-1 transformed T-cell lines, MT-2, C10/MJ, and C8166
were maintained in RPMI 1640 and 10% fetal bovine serum. MT-2 and
C10/MJ cells produce HTLV-1 virions, and C8166 does not. Cells were
pelleted and resuspended in AIM-V medium (supplemented with 2%
fetal bovine serum), and virus stocks were harvested after 24 h. Super-
natants were cleared by low speed centrifugation and filtered through
0.45-m pore size low protein-binding filters. Virus particles were col-
lected by ultracentrifugation, as described above.
Antibodies—A 15-amino acid-long synthetic peptide, NH2-Cys-
SENKTQQTPGTIKF-COOH (ProSci, Inc.), which contained a cysteine
residue at the amino terminus and amino acid residues 204–217 of the
mature HTLV-1 RT, was used to raise rabbit antiserum designated as
anti-RTM. An aliquot of the affinity-purified antibody was biotinylated
(Molecular Probes, Inc., Eugene, OR) and used to detect immunopre-
cipitated Pol products. In addition, a previously described rabbit poly-
clonal antibody that recognizes amino acids 4–16 of HTLV-1 RT, des-
ignated as anti-RTN,was used to detect Pol products (30). Hemagglutin-
tagged Pol products were immunoprecipitated with an agarose-
conjugated anti-HA antibody (Covance clone 16B12). A ratmonoclonal
antibody (Roche Applied Science clone 3F10) was used for chemilumi-
nescent detection of immunoprecipitated HA-tagged protein. Amouse
monoclonal antibody (Santa Cruz Biotechnology, Inc. (Santa Cruz, CA)
clone F-7 or Covance clone 16B12) was used to detect the epitope-
tagged Pol products on Western blots of VLP lysates. A mouse mono-
clonal antibody (Zeptometrix clone 46/6.11.1.3) specific for HTLV-1
MA (p19) was used to monitor Gag processing.
Immunoblotting—VLPswere lysed in LDS sample buffer (Invitrogen)
and denatured under reducing conditions prior to separation on 4–12%
Bis-Tris gels in MES buffer or 10% Bis-Tris gels in MOPS buffer. Pro-
teins were transferred to Immobilon-P (Millipore) membranes for
immunodetection. In most cases, blots were probed with a horseradish
peroxidase-conjugated secondary antibody and visualized by chemilu-
minescence. Blots of immunoprecipitated proteins were probed with
biotinylated anti-RTM and detected by avidin-horseradish peroxidase
and chemiluminescent staining.
Immunopurification—VLPs were lysed in LDS sample buffer
(Invitrogen). One-fifth of the volumewas reserved for analysis byWest-
ern blotting, and the remaining lysate was diluted 20-fold in radioim-
mune precipitation buffer. The viral lysates were precleared with agar-
ose-conjugated normal mouse IgG for 1 h at room temperature and
then incubated overnight with agarose-conjugated mouse anti-HA
(Covance). After the overnight incubation, the agarose beads were
washed five times with radioimmune precipitation buffer before eluting
bound protein with LDS sample buffer. The VLP lysate and immuno-
purified samples were heated at 70 °C for 10 min under reducing con-
ditions, loaded onto a 10% Bis-Tris polyacrylamide gel, and separated at
150 V in MOPS buffer. Proteins were transferred to an Immobilon P
membrane (Millipore), probed with biotinylated anti-RTM, and
detected by avidin-horseradish peroxidase and chemiluminescent
staining.
In Vitro RT Assays—Reverse transcriptase assays were performed
with a bacteriophage MS2 RNA template and a corresponding primer.
The template-primer was prepared by combining equimolar amounts
of MS2 RNA (Roche Applied Science) and RT-1 DNA primer (5-
GGAAGAAACTCTTGAAGGTG-3) in 20 mM Tris-HCl, pH 8.0, plus
0.1 mM EDTA. The template-primer was annealed by heating at 95 °C
for 5 min and then at 37 °C for 30 min, followed by the addition of 200
units of RNasin (Promega) or SUPERase-In (Ambion). RT reactions
were carried out in a final volume of 25l containing 20l of RT buffer
(50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM dithiothre-
itol, and 100 M dNTPs) plus 2 l (0.245 pmol) of MS2 RNA template-
primer and 3 l of virion extract. Reactions were incubated for 3 min at
37 °C followed by heating at 95 °C for 7 min. Virion extracts were pre-
pared by centrifugation of cell culture supernatants and lysis of the
virion pellet in RT extraction buffer (50 mM Tris-HCl, pH 8.0, 100 mM
NaCl, 0.1 mM EDTA, 20 mM dithiothreitol, 0.2% Nonidet P-40, 20%
glycerol, and 0.1 mg/ml bovine serum albumin) for 15 min on ice. The
DNA products were quantified by Taqman real time PCR analysis.
Real time PCR quantitation of the RT reaction products was per-
formed on a Prism 7700 sequence detector (PerkinElmer Life Sciences/
Applied Biosystems). 25-l PCRs contained 5l of the RT reaction plus
20l of Taqmanmastermix (Applied Biosystems), containing 100 ng of
RT-2 primer (5-CCTAAACGAAGATCGAAAGT-3), 100 ng of RT-3
primer (5-AACCTTCGTAAGCATCTCAT-3), 100 ng of Taqman
probe (5-carboxyfluorescein-TGAGTGATATCCAGGGTGCA-6-car-
boxytetramethylrhodamine-3), 0.02 units of RNase H (Invitrogen),
0.0005 units of RNase A, and 0.02 units of RNase T1 (Ambion). Reac-
tions were incubated at 37 °C for 30 min to degrade any residual RNA
that could serve as a template for Taq polymerase (33, 34). The PCR
amplification conditions were 50 °C for 2 min followed by 95 °C for 10
min to activate the DNA polymerase and then 50 cycles of 15 s at 94 °C
and 1 min at 60 °C. Calibration curves were derived with a pCR-II
TOPOplasmid containing a cDNA segment of theMS2 genome (nucle-
otides 21–790; GenBankTM accession number V00642), whichwas seri-
ally diluted over the range of 2.5  100 to 2.5  107 molecules, as
previously described (35). RT activity is expressed as the number of
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cDNA molecules generated under these reaction conditions per pg of
Gag protein added to the reaction. The HTLV-1 p19 (MA) enzyme-
linked immunosorbent assay kit fromZeptometrix was used to quantify
the Gag protein.
InVitroCleavage of Synthetic Peptides—Oligopeptideswere obtained
from Biosynthesis Inc. (Lewisville, TX). Stock solutions and dilutions
were made in distilled water, and the peptide concentrations were
determined by amino acid analysis with a Beckman 6300 amino acid
analyzer. Stabilized, purified HTLV-1 PR was prepared as described
previously (36). Active site titration of the PR was performed using
peptide KTKVL-r-VVQPK (IB268), where r represents a reduced pep-
tide bond, as described previously (37). The PR assays were initiated by
the mixing of 5 l (34–1700 nM) of purified HTLV-1 PR with 10 l of
2 incubation buffer (0.5 M potassium phosphate buffer, pH 5.6, con-
taining 10% glycerol, 2 mM EDTA, 10 mM dithiothreitol, 4 M NaCl) and
5 l of 0.04–1.2 mM substrate. The reaction mixture was incubated at
37 °C for 1 h or overnight, and the reaction was stopped by the addition
of 180 l of 1% trifluoroacetic acid, and an aliquot was injected onto a
Nova-Pak C18 reversed-phase chromatography column (3.9 150mm;
Waters Associates, Inc.) using an automatic injector. Substrates and the
cleavage products were separated using an increasingwater-acetonitrile
gradient (0–100%) in the presence of 0.05% trifluoroacetic acid. Cleav-
age product peaks were collected and were identified by mass spectro-
metric analysis and by amino acid analysis, whichwas also used to quan-
titate the amount of products generated. Due to the estimated low Km
value, the kcat/Km value for the most efficiently cleaved peptide was
determined using a competition assay performed in triplicate, as previ-
ously described for several HTLV-1 PR substrates (38).
RESULTS
Pol Synthesis and Predicted Cleavage Products—Expression of
HTLV-1 Pol requires that two ribosomal frameshifts occur during
translation of viral mRNA. Neither frameshift is efficient; translation
produces Gag, Gag-Pro, and Gag-Pro-Pol polyprotein precursors in a
ratio of about 100:10:1 (Fig. 1A). These polyproteins assemble into an
immature virion; maturation of the virion by proteolytic processing is
predicted to produce a 98-kDa Pol precursor, containing the p1, polym-
erase, ribonuclease H, and integrase domains. Removal of p1 is required
for virion-associated RT activity and virus replication (30). There is a
predicted processing site at the junction of the RNase H and integrase
domains that would produce an IN protein of33 kDa. The combined
molecular mass of the polymerase and ribonuclease H domains is esti-
mated to be about 64 kDa. If cleavage were also to occur between the
polymerase and RNaseHdomain inHTLV-1 RT, similar to the cleavage
that takes place in HIV-1 RT, the resulting peptides would be50 and
14 kDa, respectively.
The small amount ofmatureRTpresent in virionsmakes it difficult to
detect virion-associated HTLV-1 RT. Similar difficulties have been
encountered in investigations of the RTs of mouse mammary tumor
virus and Mason-Pfizer monkey virus, which also use two ribosomal
frameshifts to express Pol (39). We increased the expression of Gag-
Pro-Pol in HTLV-1 VLPs by inserting a base pair into the second ribo-
somal frameshift site to create the polfs construct: pCMVHTenv-polfs
(Fig. 1A) (30). This insertion mutation places the pro and pol open
reading frames in the same reading frame, increasing the production of
Gag-Pro-Pol and eliminating the expression of Gag-Pro. Polfs con-
structs efficiently produce VLPs in which Gag is processed normally
(30).
Rabbit antiserum was raised against a peptide in the pro/pol trans-
frame protein (p9), whose sequence corresponds to amino acids 4–16 of
the mature RT; this antiserum is designated anti-RTN (30). In addition,
we recently made an antiserum, designated as anti-RTM, against a pep-
tide corresponding to residues 204–217 of themature HTLV-1 RT. Fig.
1B shows an immunoblot of HTLV-1 proteins from VLPs derived from
transfected 293T cells and from virions released by productively
infected T-cell lines probed with the anti-RTM antibody. Specific bands
were not detected in supernatant from mock-transfected 293T cells
(lane 1) or from C8166 T-cells, which do not produce HTLV-1 struc-
tural proteins (lane 4). A single bandmigrating at49 kDawas detected
in VLPs from 293T cells transfected with HTLV-1 expression plasmids
(lane 2) and from chronically HTLV-1-infected T-cell lines,MT-2 (lane
5) and C10/MJ (lane 6). VLPs from 293T cells transfected with the polfs
construct contained significantly more Pol proteins than wild-type
VLPs, as evidenced by the intensity of the protein bands in lane 3.
Although the p49 band was the most intense, other bands can be seen
that migrate at 163, 98, and 62 kDa, consistent with the predicted sizes
for Gag-Pro-Pol, RT-IN, and RT, respectively. Immunoblots probed
FIGURE1.HTLV-1virion- andVLP-associatedPolproteins.A,major structural features
of the wild-type (wt) and polfs HTLV-1 expression plasmids are shownwith their respec-
tive primary mRNAs and the polyproteins that are generated from the gag initiation
codon. The locations of the major genes are shown below the viral genome. The arrows
mark the ribosomal frameshift sites on the viral mRNAs. The polyproteins are indicated
below the mRNA transcripts and reflect whether zero, one, or two frameshifts occur
during translation. The proteins present in Pol are indicated at the bottom. B, immuno-
blot showing RT-reactive proteins present in virions from transfected cells (lanes 1–3) or
HTLV-1 transformed cell lines (lanes 4–6). Lane 1, mock transfection; lane 2, 293T/pCM-
VHT-1; lane 3, 293T/pCMVHT-1env-polfs; lane 4, C8166; lane 5, MT-2; lane 6, C10/MJ.
Virus particle concentrationswere quantified byHTLV-1 p19 (MA) enzyme-linked immu-
nosorbent assay to normalize loading. Blots were probed with affinity-purified anti-RTM
antibody. The molecular masses of the prestained size markers are indicated in kilodal-
tons on the right. It should be noted that the migration of the Pol products relative to
molecular size markers on the 7% Tris acetate gel used in this experiment is different
than the relative migration of these proteins on NuPAGE Bis-Tris gels in MES and MOPS
buffer used in other figures.
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with the anti-RTN antibody gave similar results. None of these Pol prod-
ucts were detected in immunoblots of proteins from VLPs with a
mutated protease (data not shown). Although the polfs mutation
resulted in a significantly higher amount of Pol products in VLPs, the
polymerase activity associated with these virions is (at best) only about
2–3-fold higher than the polymerase activity associated with wild-type
virions rather than the 10-fold higher activity that might be expected
(Table 1).
Characterization of the Pol Cleavage Products—To identify the Pol
cleavage products observed in the immunoblots of HTLV-1 virus and
VLPs, we transfected 293T cells with a series of pCMVHT-1env-polfs
constructs encoding truncated versions of the Gag-Pro-Pol polyprotein
(Fig. 2A). Stop codons were introduced into the integrase, ribonuclease
H, or polymerase regions of pol; these will shorten the Gag-Pro-Pol
polyprotein by 163 (IN), 368 (RH), or 572 (RT) residues. Immuno-
blots of theVLP lysates were probedwith anti-RTN antibody (Fig. 2B) or
with anti-p19 (MA) antibody (Fig. 2C).
Immunoblots probed with anti-RTN antibody showed that VLP
lysates from cells transfected with pCMVHT-1env-polfs (designated
here as wild type) produce bands of 163, 98, 62, and 49 kDa and a
smaller band of about 17 kDa (Fig. 2B, lane 1); as seen previously, the p49
band was the most intense. The 163-kDa band, which is Gag-Pro-Pol,
shows an appropriate decrease in size in the IN (lane 2), RH (lane 3),
and RT (lane 4) mutations. As expected, these high molecular weight
bands were detected with the anti-p19 (MA) antibody (Fig. 2C). The
band in lane 1 running at98 kDa is RT-IN; its size is decreased to80
kDa in the INmutant (lane 2). The p62 band corresponds to RT, since
it was not affected by the INmutation, but it was reduced to57 kDa
in the RHVLPs. The p49 protein was present in all VLPs except those
from the RTmutant, which caused this band to shift to35 kDa. The
p49 protein is derived by the proteolytic cleavage of RT-IN or p62 RT,
and it contains the N terminus of RT, because the anti-RTN antibody
recognizes it. Likewise, the band migrating at17 kDa, which appears
to be present in all VLPs except RT, is believed to be an N-terminal
fragment of RT.
We monitored the effects of the Pol truncations on HTLV-1 Gag
processing, because it has been reported that truncations of the HIV-1
pol domain impair and interfere with proper virion assembly, release,
and maturation of virus particles (40, 41). Although the polfs mutation
resulted in the accumulation of more pr53 Gag polyprotein precursor
compared with wild-type VLPs, the Pol truncations did not cause Gag
processing defects or appear to affect the packaging of Gag-Pro-Pol in
VLPs (Fig. 2C). In vitro reverse transcription of bacteriophage MS2
RNA, quantified by Taqman real time PCR, was used to measure the
level of virion-associated RT activity of the Pol truncation mutants
(described below). As expected, the truncation (RH) or deletion
(F442am) of the RNase H domain eliminated the polymerase activity of
RT (Table 1). The absence of a full-length integrase domain (IN,
IN-HA, IN-HA-psite, and RH-HA) had no noticeable effect on polym-
erase activity (data not shown forIN). Furthermore, polymerase activ-
ity was not affected when a portion of the IN domain was fused to RT
(IN-HA-psite) or when IN was replaced with an HA tag (RH-HA).
These data indicate that Gag-Pro-Pol packaging into VLPs, Gag-Pro-
Pol processing, and polymerase activitywere not affected by the absence
of the IN domain; nor did polymerase activity require cleavage of IN
from RT.
RT-IN Cleavage—Sequence alignments suggested that the most
likely site for RT-IN cleavage was 582VL2QL585, with the scissile bond
located between Leu583 and Gln584 (28, 30), although the recent in vitro
TABLE 1
Virion-associated RT activity
Virus-like particles were concentrated from supernatants of 293T cells transfected
with wild type or mutant HTLV-1 expression plasmids. VLP lysates were added to
RT reactions containing an MS2 RNA template-primer. The amount of MS2 RNA
converted to cDNA was quantified by Taqman real time PCR analysis as described
under “Materials and Methods.” RT activity is expressed as an average of the num-




pCMVHT-1env-polfs IN-HA 1.2 0.11
pCMVHT-1env-polfs IN-HA-psite 1.0 0.16
pCMVHT-1env-polfs RH-HA 6.0 1.8
pCMVHT-1env-polfs RH 0.0068 0.0067
pCMVHT-1env-polfs F442am 0.00053 0.00028
pUC19 0
FIGURE2. Identificationof thePol cleavageproductspresent inHTLV-1VLPs.A, stop
codons were inserted into the pol gene to generate truncated Pol proteins. The esti-
mated sizes of the resulting Pol proteins are shown. B, VLPs from 293T cells transfected
with various pCMVHT-1env-polfs expression plasmids were fractionated by SDS-PAGE
ona4–12%Bis-Tris gel inMOPSbuffer and immunoblottedwith anti-RTMantibody. Lane
1, wild type (wt); lane 2, polfs; lane 3, polfsIN; lane 4, polfsRH; lane 5, polfsRT; lane 6,
mock transfection. C, a parallel immunoblot of the same samples as in Bwas run in MES
buffer andprobedwith anti-p19 (MA) antibody. Themolecularmasses of theMagicMark
(B) and prestained size markers (C) are indicated to the left of each panel, and the viral
proteins are indicated on the right.
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cleavage of a synthetic peptidewith recombinantHTLV-1 protease sug-
gested a slightly different, overlapping cleavage sequence, 584QL2SP587
(42). To determine if 582VLQL585 is part of the in vivo RT-IN cleavage
site, we inserted an HA epitope tag into the integrase region of the polfs
construct to create IN-HA (Fig. 3A). In this construct, 142 amino acids
at the C terminus of IN are replaced with an 11-amino acid HA epitope
tag. The VLQL sequence of IN-HAwas changed to GAQA to create the
IN-HA-psite mutant (Fig. 3A). Immunoblots of VLPs produced by the
IN-HA construct were probed with either anti-HA antibody or anti-
RTN antibodies to identify the N-terminal and C-terminal cleavage
products. The unprocessed Pol precursor was 75 kDa and was
detected with both the anti-HA and anti-RTN antibodies (Fig. 3, B and
C). Cleavage between RNase H and IN domains produced the expected
IN-HA fragment of 19 kDa, which was detected by anti-HA antibody
(Fig. 3B, lane 1), and a 62-kDa RT fragment containing the polymerase
and RNase H domains, which was detected with the anti-RTN antibody
(Fig. 3C, lane 1). The 19-kDa IN-HA peptide and 62-kDa RT were not
observed in IN-HA-psite VLPs (Fig. 3C, lane 2), indicating that the
VLQL to GAQA mutation prevented proteolytic cleavage. This sug-
gests that the C terminus of RT is contained within the sequence
582VLQL585, although our data are unable to resolve whether the cleav-
age occurs between Leu583 andGln584 (28) or between Leu585 and Ser588
(42).
In addition to the Pol cleavage products that correspond to RT (62
kDa) and IN-HA (19 kDa), a 35-kDa band was detected with the
anti-HA antibody (Fig. 3B, lanes 1 and 2) that is consistent with an
RH-IN-HA fragment generated by cleavage within p62 RT. There is
more of the RH-IN-HA cleavage product in the IN-HA-psite mutant
VLPs compared with the IN-HA VLPs, presumably because this prod-
uct cannot be cleaved to produce the 19-kDa IN-HA fragment. The
expected N-terminal product from cleavage of the p62 RT at this site
would be the 49-kDa polymerase protein, which was detected with the
anti-RTN antibody (Fig. 3C, lanes 1 and 2). In addition, the 17-kDa band,
which we believe to be an N-terminal RT fragment produced by further
cleavage of p49, was present in both the IN-HA and IN-HA psite VLPs.
Internal Cleavage of p62 RT—To examine the processing of p62 RT,
we inserted a sequence encoding an HA epitope tag after Leu583, near
the end of the RH domain, to construct RH-HA (Fig. 4A). Pol products
in the RH-HA VLP lysates were examined by immunoblotting with
anti-HA or anti-RT antibodies. Both the anti-HA and anti-RTN anti-
bodies detected unprocessed p62 RT protein (Fig. 4B). The anti-RTN
antibody also detected the 49- and 17-kDa proteins seen in Figs. 2B and
3C, whereas the anti-HA antibody detected a 15-kDa C-terminal cleav-
age product that would correspond to the HA-tagged RNase H domain.
This 15-kDa cleavage product is analogous to the 35-kDa RH-IN-HA
product observed in IN-HA VLP lysates (Fig. 3B), which contained
about 20 kDa of IN-HA fused to the RNase H domain. Taken together,
these data indicate that the 62-kDa RT protein is cleaved at an internal
site to yield a 49-kDa N-terminal fragment comprising the polymerase
domain and a 15-kDa C-terminal fragment comprising the RNase H
domain.
Based on the apparent molecular weight of the p49 N-terminal pro-
tein and 15-kDa C-terminal fragment, we predicted the internal cleav-
age site to be between RT residues 440 and 450 (Fig. 4C). We converted
Phe442 to a stop codon to create the F442am provirus mutant (Fig. 4, A
and C). Proteins from VLPs produced by F442am were run alongside
proteins from RH-HA VLPs and immunoblotted with anti-RTM anti-
body (Fig. 4B, right). The truncated RT protein detected in F442am
VLPs always runs a fraction slower than p49, indicating that the internal
cleavage site in wild-type RT is just upstream of Phe442. To map the
cleavage site(s) near Phe442 that gives rise to p49, we analyzed four
oligopeptides as substrates for HTLV-1 PR in an in vitro cleavage assay.
These peptides, D1 (KPVKALMPVFTLSK), D2 (KALMPVFTLSPVIK),
D3 (KPVFTLSPVIINTK), and D4 (KVIINTAPCLFSDK), contain over-
lapping sequences from the RT polymerase/RNase H boundary and
FIGURE 3.Mutation of the RT-IN protease cleavage site. A, schematic representation
of the Pol precursors made by the IN-HA mutants. The polymerase (polym), RH, and IN
domains of Pol are indicated. The IN-HA-psite construct has a mutation in the predicted
protease cleavage site between RT and IN. B, VLPs obtained from supernatants of 293T
cells transfected with pCMVHT-1env-polfs-IN-HA (lane 1) or pCMVHT-1env-polfs-IN-
HA-psite (lane 2) were immunoblotted and probed with anti-HA antibody. Molecular
masses of the prestained sizemarkers are indicated in kilodaltons on the left. C, the same
constructs as in Bwere immunoblotted and probed with anti-RTN antiserum. The major
Pol products are indicated on the right, with labels in parentheses denoting products
appearing in B.
FIGURE 4.Protease cleavage sitewithin p62RT.A, schematic representation of the Pol
precursors made by the RH-HA and F442am constructs. The polymerase (polym) and RH
domains are indicated. B, the immunoblot on the left shows anti-RTN-reactive material
present in VLPs obtained from the supernatant of 293T cells transfected with the RH-HA
mutant. The same blot, stripped and probed with monoclonal anti-HA antibody, is
shown in the middle. The immunoblot to the right shows anti-RTM-reactive material
present in VLPs fromcells transfectedwith the RH-HAand F442ammutants.C, the nucle-
otide and the predicted amino acid sequences of RT at the polymerase and ribonuclease
H domain boundary are shown. The nucleotide changes used to introduce an amber
stop codon into theRT coding sequenceat Phe442 are indicatedabove the sequence. The
arrow indicates the cleavage site predicted by Trentin et al. (28).
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additional lysine residues at the termini (underlined) to improve solu-
bility (Fig. 5A). Peptide D1 appeared to be a very efficient substrate of
HTLV-1 PR, since it was completely cleaved into two fragments at the
M2P site (Fig. 5B). Peptide D2 was also hydrolyzed very efficiently,
yielding three major identified fragments as a result of cleavage at both
the M2P and S2P sites (Fig. 5B). Peptide D3 was hydrolyzed very
inefficiently (less than 10%); overnight incubation yielded a small
amount of KPVFTLS as cleavage product, indicating an inefficient
cleavage at the S2P site. Peptide D4 remained intact, even when it was
incubated overnight with concentrated HTLV-1 PR (data not shown).
An attempt was made to determine the kinetic parameters for peptide
D1 using the Michaelis-Menten approach; however, due to its low Km
value, we were able to estimate only kcat, which was 1.12 0.06 s1. The
specificity constant (kcat/Km) was determined by competition assay
using KTKIL2VVQPK, which is an efficient substrate that has a
kcat/Km of 63.1 mM1 s1 (38). This assay provided a kcat/Km of 95.9
6.5 mM1 s1 for peptide D1. These experiments show that a protease
cleavage site within RT is an excellent substrate for HTLV-1 PR, which
hydrolyzes the bond betweenMet439 and Pro440. This cleavage gives rise
to the p49 peptide and a smaller fragment containing the RNase H
domain.
Virion-associated RT Complex—To test the hypothesis that the
HTLV-1 RT complex is a heterodimer of p62 and p49, we immunopre-
cipitated HA-tagged Pol products from RH-HA VLPs using anti-HA
antibody-coated beads. If p62 RT is a monomer or homodimer, we
would expect to purify only the HA-tagged p62; if HTLV-1 RT is a
heterodimer, the untagged p49 subunit should co-purify with the HA-
tagged p62 RT subunit. Virus-like particles were harvested from the
supernatants of 293T cells transiently transfected with RH-HA or
F442am DNA. The F442am mutant expresses only the untagged pseu-
do-p49 protein and served as a control for any nonspecific carryover of
p49 through the immunoprecipitation.
Samples of VLP lysates or anti-HA immunoprecipitates were sepa-
rated by SDS-PAGE, immunoblotted, and probed with biotinylated
anti-RTM antibody (Fig. 6). No bands were detected in concentrated
supernatants from mock-transfected cells (lanes 1 and 4). As expected,
VLPs from the F442ammutant contained the pseudo-p49 protein (lane
2), but this protein did not bind to the anti-HA beads (compare lanes 2
and 5). In contrast, p49 was detected in anti-HA immunoprecipitates of
RH-HAVLPs (lanes 3 and 6), indicating an association between p49 and
p62-HA. These results provide strong evidence in favor of HTLV-1 RT
being a p62/p49 heterodimer. Despite the fact that the quantity of p49
detected in VLPs was often substantially greater than that of p62 (see
Figs. 1A, 2B, 3C, 4B, and 6, lane 3), the p49/p62 ratio in immunoprecipi-
tateswas close to 1:1. The predicted size of the heterodimer is consistent
with the published size (95 kDa) of the virion-associated RT activity
(25).
DISCUSSION
Characterizing the maturation of virion-associated HTLV-1 Pol pro-
teins is a necessary first step in determining if the postentry block to
efficient HTLV-1 infection is related to the quantity or quality of RT.
Defining themature forms of HTLV-1 Pol proteins is also a prerequisite
for producing recombinant RT for use in future structure-function
analyses. The major barrier to analysis of Pol protein maturation is the
very small amount of Pol that is packaged into HTLV-1 particles. How-
ever, the quantity of RT does not entirely account for the low infectivity
of HTLV-1, because increasing the amount of Pol incorporated into
VLPs did not improve infectivity (5) and only slightly increased virion-
FIGURE 5. Determining p62 RT internal cleavage site using oligopeptides. A, amino
acid sequence of HTLV-1 RT at the boundary between polymerase and ribonuclease H
domains. The sequence of overlapping peptides D1–D4 that cover the region of interest
are shownbelow the protein sequencederived from the clonedprovirus. Lysine residues
added to increase the solubility of peptides are underlined. The major and minor cleav-
age sites determined here are indicated with boldface type or downward arrows, respec-
tively. B, high pressure liquid chromatography chromatograms of oligopeptides D1 and
D2, which were incubated in the presence or absence of purified HTLV protease as
described under “Materials and Methods.” Overnight incubation yielded complete
cleavage of both peptides, yielding the following fragments identified by amino acid
analysis and mass spectometry: P1/D1 (KPVKALM), P2/D1 (PVFTLSK), P1/D2 (KALM),
P2/D2 (PVFTLS), and P3/D2 (PVFTLSPVIK).
FIGURE6. Immunoprecipitationofap62/p49complex.VLPswereprepared from293T
cells transfected with RH-HA or F442ammutants or frommock-transfected cells. A frac-
tion of the VLP lysate was used directly for immunoblotting (lanes 1–3). The remainder
was immunoprecipitated with anti-HA antibody-coated beads. After extensive washes,
the p62 RT-HA protein bound to the beads was eluted and separated by SDS-PAGE and
examined by immunoblotting with anti-RTM antibody (lanes 4–6). Protein size markers
are indicated on the left, and positions of p62 and p49 are shown to the right.
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associated polymerase activity (Table 1). To detect Pol proteins in VLP
lysates by immunoblotting, we mutated the second ribosomal frame-
shift site in HTLV-1 expression vectors to significantly increase the
amount of Pol incorporated into VLPs. We detected VLP-associated
proteins corresponding to the Gag-Pol polyprotein, RT-IN, RT, and
smaller RT cleavage products. The major Pol protein in lysates of VLPs
from transfected cells or virions from chronically infected T-cell lines
was not p62 RT but rather a 49-kDa protein containing the amino-
terminal portion of p62 RT that encodes the polymerase domain.
The location of the protease cleavage site between RT and IN that has
been identified here confirms the location predicted from amino acid
sequence analysis (40) and in vitro peptide cleavage experiments (21).
However, the usefulness of sequence analysis to predict cleavage sites
involved in Pol maturation is limited. Sequence analysis was unable to
predict the additional cleavage site between PR and RT that was previ-
ously shown to generate the amino terminus of RT (5) and RT sequence
alignments did not predict the cleavage site within RT that is used to
yield p49 (40). Trentin et al. (28) predicted that if cleavage occurred, the
scissile bond would be located in the sequence 453LFSD456 between
Phe454 and Ser455. Mutation of the LFSD sequence to AASD in the
RH-HA provirus did not alter RT processing (data not shown). Initially,
our studies indicated that the internal RT cleavage site was located in
the vicinity of Pol amino acid position 440, because the native p49 frag-
ment was just a bit larger than a protein expressed from the virus that
encodes a stop codon at Phe442, but attempts to sequence the immuno-
precipitated RH-HA fragment suggested that a putative cleavage site
might exist between Ser445 and Pro446. Four oligopeptides having over-
lapping sequences of the RTpolymerase/RNaseHboundarywere tested
as substrates of the HTLV-1 PR in an in vitro assay. A similar mapping
strategy was previously successfully utilized to determine the cleavage
site in the corresponding region of equine infectious anemia virus
reverse transcriptase (43). Analysis of cleavage products identified a
major cleavage site between Met339 and Pro440 and a substantially less
efficient site between Ser445 and Pro446. Previous specificity studies of
retroviral proteases established that the most important determinant of
specificity is the P2–P2 region (nomenclature is according to Schechter
and Berger (44)) of a substrate (45). Detailed specificity studies of
HTLV-1 PR suggested that efficient cleavage sites require Leu, Ile, orVal
at P2; Leu, Met or Phe at P1; Pro, Phe, Val, or Ala at P1; and Leu, Ile, or
Val at P2 (37, 38). The LM2PV cleavage site conforms very well with
these specificity determinants, whereas the inefficient LS2PV site does
not contain an optimal P1 residue. The cleavage of HTLV-1 p62 RT to
generate p49 is reminiscent of the processing of the HIV-1 p66 RT
subunit to produce the p51 subunit. The existence of p49 in HTLV-1
virions suggests thatHTLV-1 RT could be a p62/p49 heterodimer, anal-
ogous to the p66/p51 RT heterodimer of HIV-1. Our immunoprecipi-
tation results indicate that HTLV-1 RT can form a p62/p49 het-
erodimer; whether HTLV-1 RT functions as a heterodimer in vivo
awaits further biochemical analysis.
HTLV-1 virions produced by transfected cells and chronically
infected cell lines contained greater quantities of p49 polymerase than
the p62 RT protein, whichmay contribute to the low enzymatic activity
of virion-associated RT. In contrast, HIV-1 Pol processing is regulated
so that p66 and p51 are produced in nearly equal amounts. Like the
HIV-1 p51 protein, the HTLV-1 p49 protein cannot catalyze reverse
transcription by itself; RT activity requires the catalytic p66 subunit. Pol
processing is controlled in part by Pol structure, since there are muta-
tions in HIV-1 Pol that cause overprocessing and result in the accumu-
lation of an excess of p51 (46, 47). Regardless of whether HTLV-1 is a
monomer or heterodimer, the overprocessing of HTLV-1 Pol to yield
predominantly p49 and low amounts of p62 RT could underlie the rel-
atively low polymerase activity and poor infectivity of cell-free virus
particles. An important question for the future is why HTLV-1 Pol
processing is notmore stringently regulated tomaintain higher levels of
p62 RT.
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